Lonza Just Gave Back the Tech It Bought Eight Years Ago

Lonza already announced plans to exit its Capsules & Health Ingredients business, a segment that made up 17% of its 2023 revenue. It snapped up the Genentech Vacaville facility in 2024 to boost U.S. biologics capacity. And it reorganized from a sprawling structure of three divisions and nine business units into just three integrated CDMO platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities.

The results have been encouraging. Lonza posted CHF 6.6 billion in sales in 2024, with a 29% core EBITDA margin. Its CDMO business grew 21% in the first half of 2025.

So where does personalized medicine fit? Increasingly, it doesn't. Personalized therapies are high-touch, low-volume, and operationally distinct from Lonza's bread-and-butter large-scale manufacturing. It's like a catering company deciding it would rather focus on banquets than custom birthday cakes. Both are food. Both require skill. But they're fundamentally different businesses.

Octane's Big Bet on Getting Its Baby Back

For Octane Medical Group, this is a homecoming.

The Canadian company, co-founded by CEO Timothy Smith and COO Ian Grant, originally built the Cocoon Platform out of research in bioprocesses, biomaterials, and (no joke) microgravity experiments on the Space Shuttle. Octane has quietly been assembling pieces for a bigger play in regenerative medicine. In 2024, it acquired B. Braun's orthobiologics business, expanding its footprint in bone and tissue repair.

Now, with the Lonza acquisition, Octane gets back its core technology along with an established customer base and experienced workforce. The company has committed to supporting all existing and future Cocoon customers, signaling continuity rather than disruption.

Octane isn't a household name, and there's no public information about major venture rounds or institutional investors. But the company's leadership team brings decades of experience across medical devices, biotech, and regulatory affairs. Robert C. Spiro, Global CEO of subsidiary Octane Biotherapeutics, holds over 25 patents and 40 publications. This isn't a group winging it.

The Bigger Picture: A CDMO Market on Fire

This deal lands in the middle of a cell and gene therapy manufacturing market that's growing at a staggering pace. Growth projections are eye-popping, with CAGRs (compound annual growth rates) between 23% and 28% through the next decade.

The drivers are familiar: more clinical trials, more approved therapies (especially CAR-T treatments for cancer), and increasing reliance on outsourced manufacturing as biotech companies realize they'd rather not build their own factories.

Consolidation is accelerating too. CDMOs are merging and acquiring to build capacity, add capabilities, and lock in customers. In that context, Lonza shedding a niche personalized medicine unit while a focused player like Octane absorbs it makes a certain strategic logic. Lonza gets to double down on scale. Octane gets to double down on specialization.

So, Who Wins?

It's tempting to call this a clean win-win, but the truth is more nuanced. Lonza is betting that its future lies in being the biggest, most efficient CDMO on the planet, and personalized medicine (with its one-patient-at-a-time complexity) doesn't fit that vision. That's a defensible call.

Octane, meanwhile, is betting that personalized cell therapy is the future of medicine and that owning the manufacturing infrastructure will be enormously valuable as demand scales. Also defensible, especially given where the market is heading.

The risk? Octane is a much smaller company taking on a significant operation without (as far as we know) massive financial backing. Scaling personalized medicine manufacturing requires capital, regulatory expertise, and patience. Lonza had all three and still decided to walk away.

No analyst commentary has surfaced yet on this deal, which is telling in itself. The market is watching, but it's not panicking. For now, this looks like two companies reading the same map and choosing different roads. The question is which one leads somewhere worth going.

The FDA Just Gave Old Drugs a New Shield Against Generics

The FDA just released a draft guidance explaining how drugmakers can earn three years of generic-free protection for already-approved drugs. It's one of pharma's most powerful (and most confusing) tools, and the new rules finally make it readable.